MHRA-100065-PIP01-21-M01 (update)

Key Facts

Active Substance
Active Substance:
  • TICAGRELOR
Invented Name
  • Brilique
  • Brilique
  • Brilique
  • Brilique
PIP Number MHRA-100065-PIP01-21-M01 (update)
Pharmaceutical form(s)
  • Tablet
  • Film-coated tablet
  • Orodispersible tablet
Therapeutic area
  • Cardiovascular Diseases
  • Haematology-Hemostaseology
Conditions / Indications
Conditions / Indications:
  • Prevention of thromboembolic events
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Yes
Compliance Check Decision Date
Compliance opinion date
22/09/2021
Compliance Check Procedure Number
Compliance procedure number
MHRA-100065-PIP01-21-M01-C1

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):TICAGRELOR.pdf
Published Date 03/11/2021